Evidence · condition
Parkinson's disease
LAST REVIEWED 2026-09-22 · CASE-LEVEL · NOT PROVEN
Ibogaine is not an established Parkinson's treatment. The public human record at this review is dominated by a single peer-reviewed case report using validated PD instruments, plus preclinical / transporter-chaperone literature sometimes cited in media. Case ≠ confirmatory evidence.
Is ibogaine proven for Parkinson's disease?
No — not established. A single case cannot establish efficacy, generalizability, or safety. Media and podcast PD anecdotes (including Listening Library Parkinson themes) stay media-labeled until denser primary literature exists.
- Evidence level
- Single published human case report + preclinical mechanism papers
- Design quality
- n=1 open observation; no controlled PD trials identified in this review pass
- What is not proven
- Ibogaine as a disease-modifying or symptomatic PD standard of care
- Safety
- Age, cardiac status, polypharmacy, and QT themes still apply — Safety / QTc
- Self-treatment
- Out of scope — DIY refusal
What exists (source-labeled)
Human case report (Journal of Psychedelic Studies)
Erny T, Cano Montenegro EY, Barth J, Noller G. “Ibogaine for the treatment of Parkinson's disease: A case report.” Journal of Psychedelic Studies. DOI 10.1556/2054.2025.00478 (Crossref; University of Otago research portal also lists the article). Authors report pre/post changes on validated PD instruments (including UPDRS and PDQ-39 domains among others) in one patient. Label: n=1 case report — hypothesis-generating only. IbogaBase does not reproduce regimens or dosing from the paper.
Preclinical / transporter literature (not clinical PD proof)
Mechanism papers on dopamine-transporter pharmacochaperoning and related models are sometimes cited when media discuss Parkinson-adjacent ibogaine hypotheses. Example indexed work: Asjad HMM et al., “Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism,” J Biol Chem 2017. PMID 28972153, DOI 10.1074/jbc.M117.797092. Animal / cellular models ≠ human PD efficacy.
Media adjacency
Listening Library entries that raise Parkinson themes (e.g., Ibogaine Uncovered #62 / Tobias Erny; Dickinson Part 2 neuroregen speculation) are media-labeled. Prefer this evidence page + the DOI above over podcast certainty.